Transferrin saturation (TSAT) is the percentage of transferrin—the iron-transport protein in blood—that is actively carrying iron. It is one of the most direct single-number measures of iron status: low TSAT (<20%) signals iron deficiency (absolute or functional), while high TSAT (>45% in men, >35% in women) triggers screening for hereditary hemochromatosis and iron overload.
This is a derived biomarker — calculated from serum iron and total iron-binding capacity (TIBC), or equivalently from serum iron divided by serum transferrin concentration. Calculated as: (serum iron × 100) / TIBC.
Analyzed in accredited Swedish clinical laboratories (ISO 15189). Used to support clinician-directed evaluation and monitoring. Not a stand-alone diagnosis.
Yes, if you want to understand your true iron status or screen for iron overload. TSAT is the single most sensitive test for detecting both iron deficiency and iron overload — more accurate than ferritin or serum iron alone, because it accounts for the total iron-carrying capacity of your blood. Concern about energy levels, frequent infections, or family history of hemochromatosis are all legitimate reasons to measure it.
Standard Swedish vårdcentral practice includes TSAT as part of a routine iron panel when investigating fatigue, anemia, or metabolic dysfunction. In the Swedish population, where hemochromatosis is more prevalent than in Southern Europe, TSAT is especially valuable for early detection of iron excess — a condition that can silently damage your liver, heart, and pancreas over years if missed.
Detects iron deficiency early. Low TSAT (<20%) flags absolute iron deficiency or iron-restricted erythropoiesis before hemoglobin drops; critical for premenopausal women, vegetarians, and people with chronic inflammation.
Screens for hemochromatosis and iron overload. High TSAT is the first-line screening marker for hereditary hemochromatosis (HFE mutation); European guidelines recommend HFE genetic testing when TSAT is persistently elevated (>45% in men, >35% in women).
Clarifies iron status when ferritin is ambiguous. Ferritin rises in inflammation and liver disease, making it an unreliable iron indicator in isolation; TSAT separates true iron burden from inflammatory noise.
Tracks response to iron supplementation. TSAT rises predictably after iron intake, making it an excellent marker to confirm that supplementation is working and to avoid iron overload.
Guides clinical decision-making in anemia of chronic disease. In infection, inflammation, or malignancy, iron and TIBC both drop, keeping TSAT near-normal—but ferritin remains high, revealing that the low iron is intentional (not deficiency) and iron supplementation will worsen outcomes.
The physiology. Transferrin is a protein synthesized by the liver that binds iron in the bloodstream and transports it to cells that need it—red blood cells, mitochondria, immune cells—or to iron-storage sites (liver, spleen). Each transferrin molecule has two binding sites, so not all transferrin is occupied with iron at any moment. TSAT measures the percentage of those sites that are filled: a simple ratio of serum iron concentration divided by the total iron-binding capacity (TIBC, the maximum iron that all transferrin in blood can carry).
Why it matters for longevity. Too little iron and you cannot make hemoglobin, myoglobin, or iron-sulfur clusters in mitochondria—energy production collapses, immune function suffers, and you become anemic. Too much iron, and the excess iron catalyzes free-radical damage (Fenton chemistry) that oxidizes lipids, proteins, and DNA in every tissue—heart, liver, pancreas, and brain are especially vulnerable. TSAT is sensitive to both extremes. It also reveals the *fractional saturation* at any moment: if TSAT is very high, iron is flooding in faster than cells can use or store it safely, which is the hallmark of iron overload. If TSAT is very low despite normal ferritin, iron transport is the bottleneck—a sign of functional iron deficiency in the setting of chronic inflammation.
Identifies hemochromatosis before organ damage. Hereditary hemochromatosis (HFE-C282Y homozygosity) affects up to 1 in 200 people of Northern European descent and is overrepresented in Sweden. Early iron overload causes no symptoms but damages the liver (cirrhosis, hepatocellular carcinoma), heart (arrhythmia, cardiomyopathy), and pancreas (diabetes) irreversibly. Elevated TSAT triggers genetic testing and phlebotomy, which is curative if started before fibrosis sets in.
Detects iron deficiency that impairs mitochondrial function and immune response. Low TSAT predicts not only anemia but also impaired T-cell function, reduced exercise capacity, and poor wound healing—especially in women of childbearing age and in people on plant-based diets or with malabsorption.
Contextualizes ferritin in inflammation. Ferritin is an acute-phase reactant, so it rises dramatically in any infection, autoimmune disease, or metabolic stress. TSAT separates true iron burden from inflammatory signaling: low TSAT + high ferritin = anemia of chronic disease (iron is sequestered defensively), whereas high TSAT + high ferritin = true iron overload.
Guides personalized iron strategy in the Swedish population. Sweden has higher hemochromatosis prevalence and higher ferritin reference ranges than Southern Europe. Standard TSAT targets (20–40%) are aligned with Swedish clinical practice and hereditary hemochromatosis screening thresholds endorsed by European societies.
Standard Swedish reference (vårdcentralen): 20–45% in men, 15–50% in women (age-dependent; reference labs vary slightly). Below 20% signals iron deficiency; above 45% in men or 35% in women triggers hemochromatosis screening.
Loovi optimal (longevity): 25–40% in both sexes. This range reflects optimal iron transport (active use, no accumulation) and minimizes both deficiency risk and iron-overload oxidative stress.
Aggressive (hereditary hemochromatosis risk or established iron overload): < 35% via phlebotomy or chelation therapy.
The distinction matters: a TSAT of 45% is technically "normal" by standard lab reference, but it sits at the threshold of iron accumulation risk and warrants HFE genetic testing. A TSAT of 25–35% is where most healthy people without iron metabolism disorders sit and where iron-dependent tissues are functioning optimally without oxidative stress.
Low TSAT (<20%). Iron supply is insufficient to saturate transferrin. This reflects either absolute iron deficiency (depleted body stores, low dietary intake, ongoing blood loss) or functional iron deficiency (iron is being sequestered by inflammation, as in chronic infection or autoimmune disease). In absolute deficiency, ferritin is low and serum iron is low. In functional deficiency (anemia of chronic disease), ferritin is normal or high, serum iron is low, and TIBC is suppressed. Either way, iron-dependent enzymes in mitochondria, immune cells, and red blood cell precursors are compromised. Symptoms may include fatigue, reduced exercise capacity, impaired wound healing, and increased susceptibility to infection.
Optimal TSAT (20–40%). Transferrin is well-saturated but not overloaded. Iron is being delivered to cells at a healthy rate, mitochondrial function is optimal, and there is no oxidative stress from free iron. This is the target range for longevity.
High TSAT (40–50%). Transferrin is approaching full saturation. At this level, free iron (non-transferrin-bound iron) begins to accumulate, which catalyzes free-radical damage. This is the screening threshold for hereditary hemochromatosis. If TSAT is persistently >45% in men or >35% in women, HFE genetic testing is indicated (European guidelines). Some people carry HFE mutations without phenotypic hemochromatosis; others have secondary iron overload from repeated transfusions, liver disease, or chronic alcohol use.
Very high TSAT (>50%). Free iron is circulating at elevated levels, causing oxidative stress in the liver, heart, and pancreas. This is the range of active hemochromatosis or secondary iron overload. Phlebotomy (blood removal) or chelation therapy is indicated. Liver ultrasound and ferritin should also be assessed to screen for cirrhosis and fibrosis.
Factors that influence TSAT. Diurnal variation is substantial: TSAT is highest in the morning (after fasting overnight) and falls through the day, so morning fasting samples are standard. Serum iron fluctuates with recent iron intake (rises after a meal, especially one rich in vitamin C or heme iron), iron supplementation (within days), and menstrual cycle phase in women (lower in menses, higher in luteal phase). Acute infection, inflammation, or malignancy suppress both serum iron and TIBC transiently, sometimes keeping TSAT near-normal even when true iron stores are depleted. Intense exercise within 48 hours, recent blood donation, and recent vaccination can cause transient changes. For diagnostic purposes, confirm low or high TSAT on a repeat fasting morning sample before initiating treatment.
Genetics—hereditary hemochromatosis. Homozygous C282Y or H63D compound heterozygosity in the HFE gene causes constitutive hepcidin suppression, leading to unchecked intestinal iron absorption and gradual iron overload. Affects up to 1 in 200 people of Northern European ancestry; prevalence is higher in Scandinavia.
Dietary iron intake and absorption. Low intake of bioavailable iron (heme iron from meat, fortified grains, or supplementation) causes gradual depletion, especially in vegetarians, vegans, or people with malabsorption (celiac disease, inflammatory bowel disease, H. pylori infection, achlorhydria). High intake alone rarely causes overload unless there is underlying genetic predisposition.
Chronic inflammation and anemia of chronic disease. Hepcidin (the master iron-regulatory hormone) rises in infection, autoimmune disease, or malignancy, blocking iron absorption and promoting iron sequestration in macrophages. This lowers serum iron and TIBC together, keeping TSAT near-normal; the low iron is physiologically appropriate (defensive), not a deficiency requiring supplementation.
Metabolic dysfunction and insulin resistance. Insulin resistance and hepatic steatosis blunt hepcidin suppression, allowing iron accumulation even without HFE mutation. Elevated fasting glucose, triglycerides, and ferritin often accompany high TSAT in metabolic syndrome.
Blood loss and phlebotomy. Chronic low-level blood loss (heavy menstruation, occult gastrointestinal bleeding, chronic blood donation) depletes iron stores and lowers TSAT if intake does not keep pace. This is the physiological cause of iron deficiency anemia in menstruating women and in older men with GI pathology.
For low TSAT. Iron supplementation works by increasing serum iron, which increases TSAT and restores iron-dependent enzyme function. Oral ferrous iron (ferrous sulfate, ferrous fumarate, ferrous bisglycinate) is absorbed in the proximal small intestine; absorption is enhanced by vitamin C (ascorbic acid) and inhibited by phytate, polyphenols, and concurrent calcium or proton-pump inhibitors. Dose and formulation determine tolerability—ferrous bisglycinate is gentler on the gut than ferrous sulfate. If oral iron is poorly tolerated or malabsorbed, parenteral iron (intravenous iron sucrose, iron carboxymaltose) bypasses the gut and raises TSAT more rapidly. Dietary strategies include increasing heme iron (red meat, poultry, seafood), fortified grains, and legumes paired with vitamin C sources (citrus, peppers, tomatoes). If low TSAT is secondary to chronic inflammation (anemia of chronic disease), addressing the underlying inflammation—infection treatment, autoimmune disease control—is more important than iron supplementation, which can worsen outcomes by feeding pathogens or worsening inflammation.
For high TSAT. Phlebotomy (therapeutic blood removal, typically 500 mL per session, once or twice weekly) directly lowers iron and TSAT. It is the first-line treatment for hereditary hemochromatosis and is highly effective when started before cirrhosis develops. Dietary iron restriction (reducing red meat, fortified grains, and vitamin C supplements) slows iron reaccumulation between phlebotomies. Alcohol abstinence reduces iron absorption and protects the liver. In secondary iron overload (transfusion-dependent anemia, cirrhosis), iron chelation therapy (deferoxamine, deferasirox, deferiprone) binds circulating iron and promotes fecal or urinary excretion. TSAT typically falls within weeks of starting phlebotomy or chelation.
Why personalization matters. The right lever depends on the cause of abnormal TSAT—genetic vs. dietary vs. inflammatory—and the full biomarker context (ferritin, hemoglobin, TIBC, CRP, HFE genotype, liver function). This is where a Loovi longevity doctor's interpretation becomes essential: TSAT in isolation can be misleading without the broader picture.
TSAT is one number in a three-part iron status conversation. Serum ferritin tells you about iron stores (but rises in inflammation, so it can lie). Serum iron tells you the absolute amount of circulating iron (but fluctuates hour-to-hour with diet and diurnal rhythm). TSAT integrates both—it tells you the percentage saturation—but it still doesn't tell you whether inflammation is hiding iron deficiency or masking overload. Hemoglobin reveals the functional consequence of iron status on red blood cell production. TIBC (total iron-binding capacity) or transferrin concentration tells you how much transport protein is available—low TIBC in inflammation narrows TSAT's window of interpretation. C-reactive protein (hs-CRP) contextualizes whether low TSAT is true deficiency or functional deficiency in the setting of active inflammation. These markers together answer the full question: What is my actual iron status, and what should I do about it?
That is exactly what Loovi's comprehensive membership does. You get TSAT, ferritin, serum iron, TIBC, hemoglobin, and inflammatory markers (hs-CRP, ESR) all measured in one annual panel, with a 1-on-1 consultation with a longevity doctor who interprets the full profile and builds a personalized optimization plan. You also get physical tests (strength, mobility, VO2 max) to reveal functional consequences of poor iron status (fatigue, reduced exercise capacity) in real time. All of this from 295 SEK/month, 80+ drop-in clinics across Sweden, results in 3 days, and unlimited chat support. Friskvårdsbidrag-approved.
This is an important discordance pattern. High TSAT indicates that transferrin is well-saturated (more iron is circulating than usual), but if ferritin is normal, iron stores are not yet elevated. This often appears early in hereditary hemochromatosis—iron is being absorbed faster than it is being stored or used, so TSAT rises first, ferritin follows later. It is the perfect time to initiate HFE genetic testing and start monitoring, or to begin preventive phlebotomy if HFE mutation is confirmed. Waiting until ferritin is elevated risks missing the window for reversible disease.
This is the hallmark of anemia of chronic disease (inflammation masking iron status). Infection, autoimmune disease, or malignancy trigger hepcidin release, which blocks iron absorption and iron export from macrophages. The result: iron is trapped in stores (ferritin is high) but serum iron is low, so TSAT plummets. Your body is intentionally hoarding iron away from circulating blood to starve pathogens or contain inflammation. This is adaptive, not pathological. Iron supplementation will not help and may worsen infection or inflammation. Address the underlying cause—infection treatment, autoimmune control, malignancy treatment—and ferritin and TSAT will normalize as inflammation resolves. hs-CRP or ESR will be elevated in this scenario, confirming active inflammation.
In menstruating women, iron loss accelerates during menstruation, lowering serum iron slightly in the follicular phase. Some women with heavy menstrual bleeding develop persistent low TSAT and iron deficiency anemia if dietary iron intake does not compensate. After menopause, iron loss normalizes and TSAT typically stabilizes. If a woman has low TSAT and heavy menstrual bleeding, hormonal contraception (which reduces flow) or iron supplementation are the levers; investigation for underlying bleeding disorders (von Willebrand disease, platelet dysfunction) may be warranted if bleeding is severe.
TSAT is a standard test included in comprehensive iron panels at nearly all Swedish vårdcentraler and hospitals. It is covered by routine blood work for anemia investigation, fatigue, or family history screening. No private testing is required unless your local vårdcentral does not run the full iron panel; in that case, a private longevity service like Loovi can fill the gap.
Serum iron rises within hours to a day of iron intake (peak usually 2–4 hours after oral dosing on an empty stomach), so TSAT rises quickly. However, this acute bump does not reflect true iron repletion—it is transient. Meaningful improvement in iron stores (ferritin) and sustained TSAT elevation takes weeks to months of consistent supplementation. To assess true repletion, repeat testing should occur after 6–12 weeks of supplementation, on a fasting morning sample, to avoid confounding from recent meal-time iron spikes.
Yes. Removing 500 mL of blood removes ~250 mg of iron (assuming normal hemoglobin), which immediately lowers serum iron and TSAT. For someone with hereditary hemochromatosis undergoing weekly phlebotomy, TSAT typically normalizes within 2–4 weeks if iron stores are not severely elevated. If cirrhosis is already present, iron reaccumulates more slowly, but TSAT still falls as long as phlebotomy outpaces new iron absorption.
Ferritin is a storage marker—it reflects total body iron, but it also rises with inflammation (acute-phase reactant), liver disease, and malignancy, so a single ferritin value can be misleading. TSAT is a functional marker—it shows the saturation of the iron transport system right now. High TSAT with normal ferritin = early iron overload (classic early hemochromatosis). Low TSAT with high ferritin = inflammation hoarding iron (anemia of chronic disease, not deficiency). For diagnosis, both are needed; for early detection of iron metabolism trouble, TSAT is superior because it cannot be faked by inflammation.
Yes, if you have been fasting for a long time or if your blood sample was drawn in the afternoon (diurnal variation lowers TSAT). A single low TSAT is not diagnostic of iron deficiency; confirm on a repeat fasting morning sample. Very low TSAT (<10%) is uncommon and usually signals either severe iron deficiency (depleted stores, ongoing loss outpacing intake) or severe inflammation/infection (anemia of chronic disease). The clinical context—symptoms, hemoglobin, ferritin, CRP—determines the interpretation.
Hereditary hemochromatosis (HFE C282Y) is 5–10 times more common in Northern European populations, including Swedes, than in Southern European or Asian populations. Many Swedish people carry one or two HFE mutations without knowing it. Early detection via elevated TSAT and HFE genetic testing prevents decades of silent iron accumulation and cirrhosis. Standard Swedish hemochromatosis screening uses TSAT as the initial filter. Additionally, Swedish reference ranges for TSAT and ferritin are calibrated for this higher-risk population, so using European guidelines (rather than US-centric ones) is especially important for Swedish interpretation.
